BTH 1704

Drug Profile

BTH 1704

Alternative Names: AS-1402; BTH-1704; HuHMFG1; Monoclonal antibody HMFG1; R-1550; Therex

Latest Information Update: 12 Jun 2015

Price : $50

At a glance

  • Originator Cancer Research UK
  • Developer Antisoma; Biothera; University of Illinois at Chicago
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunostimulants; Mucin 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pancreatic cancer
  • Discontinued Breast cancer

Most Recent Events

  • 01 May 2014 Phase-I clinical trials in Pancreatic cancer (combination therapy, late-stage disease, second line therapy or greater) in USA (IV)
  • 11 Mar 2011 Biothera acquires rights for AS 1402 from Antisoma
  • 07 Aug 2009 Discontinued - Phase-II for Breast cancer in Europe (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top